Source: CNN Money / DOW JONES NEWSWIRES
Bristol-Myers Squibb Co. (BMY) and Gilead Sciences Inc. (GILD) Wednesday said Health Canada approved the companies' Atripla for the treatment of HIV-1 infection in adults.
The companies said Atripla, which combines Bristol-Myers' Sustiva and Gilead's Truvada, will be Canada's first once-daily single tablet HIV regimen for use as a stand-alone therapy or in combination with other antiretrovirals. The drug, developed through a joint venture between Bristol-Myers and Gilead, was approved by the Food and Drug Administration in July 2006.
In premarket activity, shares of New York health- and personal-care products maker Bristol-Myers were trading at $29.87, up about 2.2% from Tuesday's close of $29.24. Shares of Foster City, Calif., biopharmaceutical company Gilead closed Tuesday at $42.40, up 39 cents. The stock reached a 52-week high of $43.90 on Monday.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment